Bliss GVS Pharma Quarterly Results for Trading Insights
In Mar 2026, Bliss GVS Pharma (BLISSGVS) reported revenue ₹268 Cr and net profit ₹37 Cr — revenue +27.6% YoY. Also explore BLISSGVS share price charts to track price trends across different timeframes.
BLISSGVS Quarterly Results — Revenue, Profit & EPS Highlights
Bliss GVS Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse BLISSGVS annual financials for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹268 Cr in Mar 2026 (+5.9% vs Sept 2025, +27.6% vs Mar 2025)
- Net Profit of ₹37 Cr in Mar 2026 (+27.6% vs Sept 2025, +117.6% vs Mar 2025)
- EBITDA of ₹56 Cr in Mar 2026 (+7.7% vs Sept 2025)
- Operating Margin of 17.0% in Mar 2026 (-1.0pp vs Sept 2025)
- Earnings Per Share of ₹3.22 in Mar 2026 (+24.8% vs Sept 2025)
Bliss GVS Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BLISSGVS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 268 | 253 | 210 | 243 | 237 | 5.9% | 27.6% |
| Net Profit (₹ Cr) | 37 | 29 | 17 | 44 | 25 | - | - |
| EBITDA (₹ Cr) | 56 | 52 | 33 | 77 | 51 | - | - |
| EPS (₹) | 3.22 | 2.58 | 1.47 | 4.08 | 2.20 | - | - |
| Operating Margin (%) | 17.0% | 18.0% | 11.0% | 20.0% | 15.0% | - | - |
BLISSGVS Share Price Trend — 1-Year Movement Across Quarterly Results
Bliss GVS Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Bliss GVS Pharma share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BLISSGVS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bliss GVS Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores